glp 1 glucagon receptor pathway Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism New concept of signaling pathway

GHK-Cu provides structural components through collagen synthesis and matrix remodeling

MMWR Morb

Muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage ( cholinergic crisis ) An important complication that can arise is obstruction of the airway by bronchial secretions Pharmacokinetics: IV and IM administration Rapid renal excretion, resulting in a short duration of action of 5-10 mins Major drug Interactions: Care should be given when administering this drug to patients with symptoms of myasthenic weakness who are also on anticholinesterase drugs Since symptoms of anticholinesterase overdose (cholinergic crisis) may mimic underdosage (myasthenic weakness), their condition may be worsened by the use of this drug Figure 2

Users experiencing multiple GLP-1 side effects simultaneously may also benefit from the comprehensive approach